The Phase I trial will evaluate the safety and efficacy of the company's drug which targets tumours whilst leaving normal cells unharmed.
Joshua Silverwood is a journalist specializing in the medical and healthcare industry. With a focus on clinical trials, medical devices, and pharmaceutical advancements, his work has been featured in publications such as Medical Device Network, Clinical Trials Arena, Pharmaceutical-Technology, and Hospitalmanagement.net. Joshua provides insightful coverage of the latest developments and innovations in the healthcare field.